SCLXW:NSD-Scilex Holding Company (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 0.4804

Change

+0.03 (+7.02)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
AZN AstraZeneca PLC ADR

+0.19 (+0.24%)

USD 241.07B
AMGN Amgen Inc

+3.42 (+1.06%)

USD 172.56B
SNY Sanofi ADR

+0.18 (+0.35%)

USD 124.25B
GILD Gilead Sciences Inc

+1.22 (+1.77%)

USD 85.48B
BIIB Biogen Inc

+4.05 (+1.74%)

USD 33.75B
GRFS Grifols SA ADR

-0.06 (-0.67%)

USD 5.12B
AMRN Amarin Corporation PLC

-0.01 (-1.67%)

USD 0.31B
SCLX Scilex Holding Company

+0.12 (+6.49%)

USD 0.23B
MIRA MIRA Pharmaceuticals Inc. Comm..

+0.04 (+7.28%)

USD 0.01B

ETFs Containing SCLXW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.44% 100% F 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.44% 100% F 88% B+
Trailing 12 Months  
Capital Gain -64.93% 22% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.93% 22% F 15% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.24% 44% F 21% F
Dividend Return -16.24% 44% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.50% 11% F 36% F
Risk Adjusted Return -34.20% 44% F 25% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector